Pharmacokinetics of nebulized terbinafine in Hispaniolan Amazon parrots (Amazona ventralis)

Lee C Emery1, Sherry K Cox, Marcy J Souza

  • 1Class of 2013, University of Tennessee College of Veterinary Medicine, 2407 River Dr, Knoxville, TN 37996, USA.

Insights

Nebulized terbinafine hydrochloride for avian aspergillosis showed short-lived plasma concentrations. Raw drug powder yielded longer therapeutic levels than crushed tablets, suggesting optimized delivery is needed for effective treatment.

Area of Science:

  • Veterinary Medicine
  • Pharmacology
  • Avian Health

Background:

  • Aspergillosis is a challenging avian fungal disease.
  • Terbinafine hydrochloride presents potential advantages over traditional antifungals.
  • Nebulization may enhance antifungal treatment efficacy in avian lung diseases.

Purpose of the Study:

  • To determine plasma concentrations of terbinafine after nebulization in Hispaniolan Amazon parrots.
  • To compare plasma terbinafine levels from two different nebulization solutions (crushed tablet vs. raw powder).

Main Methods:

  • Six Hispaniolan Amazon parrots were divided into two groups.
  • Birds were nebulized for 15 minutes with either a crushed tablet or raw powder terbinafine solution.
  • Plasma samples were collected up to 720 minutes post-nebulization and analyzed using high-performance liquid chromatography.

Main Results:

  • The raw powder solution had a significantly higher terbinafine concentration than the crushed tablet solution.
  • No significant difference in plasma terbinafine concentrations was observed between the two groups.
  • Plasma terbinafine remained above in vitro minimum inhibitory concentrations for approximately 1 hour (crushed tablet) and 4 hours (raw powder).

Conclusions:

  • Nebulized terbinafine achieved transient plasma concentrations in parrots.
  • The raw powder formulation provided a longer duration above minimum inhibitory concentrations compared to the crushed tablet.
  • Higher concentrations, longer nebulization, or more frequent administration may be necessary for therapeutic efficacy in avian aspergillosis.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...